Gentex Announces Acquisition of BioConnect
Rhea-AI Summary
Gentex (NASDAQ: GNTX) announced on November 17, 2025 that it has acquired Toronto-based BioConnect, a provider of a multi-modal biometric authentication software platform for security and access control.
BioConnect serves more than 1,500 customers, including 8 of the top 10 US-headquartered data centers, and offers identity verification across physical, IoT, and digital applications. Gentex said the deal creates synergies with EyeLock (an iris biometric asset obtained earlier this year) and will form a combined Security & Access Control team to integrate hardware and software capabilities across automotive, aerospace, medical, and smart-home markets.
Positive
- Acquisition announced on November 17, 2025
- BioConnect serves > 1,500 customers
- 8 of top 10 US data centers use BioConnect
- Planned synergy with EyeLock biometric hardware obtained earlier in 2025
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GNTX declined 2.23%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ZEELAND, Mich., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX) announced today that it has acquired Toronto-based BioConnect, a leader in biometric authentication solutions. The company provides a market-leading, multi-modal authentication software platform for the security and access control industry.
Gentex is a technology company and long-time supplier of electro-optical products for the global automotive, aerospace, fire protection, and medical industries. The company is best known for automotive electronics, but continues to grow its capabilities in vision systems, sensing, AI development, biometrics, home automation, and other smart technologies.
BioConnect provides an enterprise biometric authentication & security platform that verifies a person’s identity across physical, IoT and digital applications. The result is exact identity assurance, advanced cybersecurity, and the protection of company assets, people, data, and IP.
“Biometric technology is playing an increasingly important role in the industries in which we operate, including automotive, aerospace, medical, and smart home,” said Gentex Chief Operations Officer and Chief Technology Officer Neil Boehm. “This acquisition not only provides Gentex with a strong foothold in the security and access control industry, but also the expertise to continue developing advanced biometric solutions for the industries we currently serve.”
“We’re excited to combine our technologies and capabilities with those of Gentex,” said Rob Douglas, BioConnect Founder and CEO. “Gentex’s engineering capabilities, software expertise, and quality, high-volume electronics manufacturing will not only help us grow in the security and access control space but also expand into new platforms and industries.”
Gentex sees synergy between BioConnect and EyeLock, an iris biometric technology obtained by Gentex in the purchase of VOXX International earlier this year. Under the leadership of Douglas, BioConnect and EyeLock personnel will work together to form Gentex’s Security & Access Control team, which has already begun collaborating on ways to utilize EyeLock hardware in BioConnect platforms in unique ways.
BioConnect currently has over 1,500 customers across many regulated industries, including data storage, healthcare, financial services, education, and manufacturing. The company has carved a niche by providing holistic security systems for IT data centers, with eight of the top 10, US-headquartered data centers already utilizing BioConnect to protect physical access to their highly sensitive operations.
About BioConnect
Established in 2010 by IT professionals for IT professionals, BioConnect provides an enterprise biometric and multi-factor authentication & security platform to establish stronger identity trust for the protection of the most valuable enterprise assets -- people, data and IP.
About Gentex
Founded in 1974, Gentex Corporation (NASDAQ: GNTX) is a technology company that leverages its core competencies, strategic partnerships, acquisitions, and ongoing research to create market-leading positions in a variety of verticals. You can view some of the Company’s latest technology at www.gentex.com.
| Gentex Media Contact Craig Piersma (616) 772-1590 x4316 craig.piersma@gentex.com | Gentex Investor Relations Contact Josh O’Berski (616) 772-1800 x5814 josh.oberski@gentex.com |
FAQ
What did Gentex (GNTX) announce on November 17, 2025?
How many customers does BioConnect have and which data centers use it?
How will the BioConnect acquisition affect Gentex's security products (GNTX)?
Which industries will Gentex target with BioConnect technology (GNTX)?
Does the announcement describe immediate customer or revenue guarantees for GNTX?
